CLENE INC (CLNN) Stock Price, Quote, News and Overview
NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD
CLNN Quote, Performance and Key Statistics
4.43
-0.08 (-1.77%)
The current stock price of CLNN is 4.43 USD. In the past month the price decreased by -7.9%. In the past year, price decreased by -48.49%.
CLNN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CLNN
Company Profile
Clene Inc. is a US-based company operating in Biotechnology industry. The company is headquartered in Salt Lake City, Utah and currently employs 82 full-time employees. The company went IPO on 2018-08-27. Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. The company specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.
Company Info
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121 US
CEO: Robert Etherington
Employees: 84
Company Website: https://clene.com/
Investor Relations: http://invest.clene.com/
Phone: 18016769695
CLENE INC / CLNN FAQ
What is the stock price of CLENE INC today?
The current stock price of CLNN is 4.43 USD. The price decreased by -1.77% in the last trading session.
What is the ticker symbol for CLENE INC stock?
The exchange symbol of CLENE INC is CLNN and it is listed on the Nasdaq exchange.
On which exchange is CLNN stock listed?
CLNN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CLENE INC stock?
12 analysts have analysed CLNN and the average price target is 51.2 USD. This implies a price increase of 1055.85% is expected in the next year compared to the current price of 4.43. Check the CLENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CLENE INC worth?
CLENE INC (CLNN) has a market capitalization of 36.90M USD. This makes CLNN a Nano Cap stock.
How many employees does CLENE INC have?
CLENE INC (CLNN) currently has 84 employees.
What are the support and resistance levels for CLENE INC (CLNN) stock?
CLENE INC (CLNN) has a resistance level at 4.46. Check the full technical report for a detailed analysis of CLNN support and resistance levels.
Is CLENE INC (CLNN) expected to grow?
The Revenue of CLENE INC (CLNN) is expected to decline by -34.68% in the next year. Check the estimates tab for more information on the CLNN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CLENE INC (CLNN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLNN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLNN, evaluating the profitability, health, valuation and growth aspects
- CLENE INC (CLNN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CLENE INC (CLNN) Sales and EPS estimates to see what analysts future expectations are.
- CLENE INC (CLNN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CLENE INC (CLNN) Insider and Institutional Ownership to learn about the owners and their transactions.
- CLENE INC (CLNN) Stock Chart to make your own analysis
- CLENE INC (CLNN) Latest news and press-releases to stay up to date.
Does CLENE INC (CLNN) stock pay dividends?
CLNN does not pay a dividend.
When does CLENE INC (CLNN) report earnings?
CLENE INC (CLNN) will report earnings on 2025-03-11, after the market close.
What is the Price/Earnings (PE) ratio of CLENE INC (CLNN)?
CLENE INC (CLNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.28).
What is the Short Interest ratio of CLENE INC (CLNN) stock?
The outstanding short interest for CLENE INC (CLNN) is 2.14% of its float. Check the ownership tab for more information on the CLNN short interest.
CLNN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLNN. When comparing the yearly performance of all stocks, CLNN is a bad performer in the overall market: 85.71% of all stocks are doing better.
CLNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLNN. CLNN may be in some trouble as it scores bad on both profitability and health.
CLNN Financial Highlights
Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -5.28. The EPS increased by 43.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLNN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to CLNN. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 55.04% and a revenue growth -34.68% for CLNN